Berta Cillero-Pastor

Dr. Berta Cillero-Pastor

The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2019 in Analytical Chemistry
Verified
Journal Article
Open access
FBFlorian P. Y. Barré
Florian P. Y. Barré
MPMartin R. L. Paine
Martin R. L. Paine
BFBryn Flinders
Bryn Flinders
ATAdam J. Trevitt
Adam J. Trevitt
PKPatricia D. Kelly
Patricia D. Kelly
RHRon M. A. Heeren
Ron M. A. Heeren
Visualizing the distributions of drugs and their metabolites is one of the key emerging application areas of matrix-assisted laser desorption/ionization–mass spectrometry imaging (MALDI-MSI) within pharmaceutical research. The success of a given MALDI-MSI experiment is ultimately determined by the ionization efficiency of the compounds of interest, which in many cases are too low to enable detection at relevant concentrations. In this work we have taken steps to address this challenge via the first application of laser-postionisation coupled with MALDI (so-called MALDI-2) to the analysis and imaging of pharmaceutical compounds. We demonstrate that MALDI-2 increased the signal intensities for 7 out of the 10 drug compounds analyzed by up to 2 orders of magnitude compared to conventional MALDI analysis. This gain in sensitivity enabled the distributions of drug compounds in both human cartilage and dog liver tissue to be visualized using MALDI-2, whereas little-to-no signal from tissue was obtained using conventional MALDI. This work demonstrates the vast potential of MALDI-2-MSI in pharmaceutical research and drug development and provides a valuable tool to broaden the application areas of MSI. Finally, in an effort to understand the ionization mechanism, we provide the first evidence that the preferential formation of [M + H]+ ions with MALDI-2 has no obvious correlation with the gas-phase proton affinity values of the analyte molecules, suggesting, as with MALDI, the occurrence of complex and yet to be elucidated ionization phenomena.

2 December 2016 in Analytical Chemistry
Verified
Journal Article
Open access
FBFlorian P. Y. Barré
Florian P. Y. Barré
BFBryn Flinders
Bryn Flinders
JGJoao Pedro Garcia
Joao Pedro Garcia
IRImke Rudnik-Jansen
Imke Rudnik-Jansen
LHLennart R. S. Huizing
Lennart R. S. Huizing
BCBerta Cillero-Pastor
Berta Cillero-Pastor
Osteoarthritis (OA), characterized by degeneration of the cartilaginous tissue in articular joints, severely impairs mobility in many people worldwide. The degeneration is thought to be mediated by inflammatory processes occurring in the tissue of the joint, including the cartilage. Intra-articular administered Triamcinolone acetonide (TAA) is one of the drug treatments employed to ameliorate the inflammation and pain that characterizes OA. However, the penetration and distribution of TAA into the avascular cartilage is not well understood. We employed matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), which has been previously used to directly monitor the distribution of drugs in biological tissues, to evaluate the distribution of TAA in human cartilage after in vitro incubation. Unfortunately, TAA is not easily ionized by regular electrospray ionization (ESI) or MALDI. To overcome this problem, we developed an on-tissue derivatization method with Girard’s reagent T (GirT) in human incubated cartilage being able to study its distribution and quantify the drug abundance (up to 3.3 ng/µl). Our results demonstrate the depth of penetration of a corticosteroid drug in human OA cartilage using MALDI-MSI.

15 July 2023 in Critical Reviews in Microbiology
Verified
Journal Article
Open access
SHS. W. G. van Hoogstraten
S. W. G. van Hoogstraten
CKC. Kuik
C. Kuik
JAJ. J. C. Arts
J. J. C. Arts
BCBerta Cillero-Pastor
Berta Cillero-Pastor
The formation of bacterial biofilms in the human body and on medical devices is a serious human health concern. Infections related to bacterial biofilms are often chronic and difficult to treat. Detailed information on biofilm formation and composition over time is essential for a fundamental understanding of the underlying mechanisms of biofilm formation and its response to anti-biofilm therapy. However, information on the chemical composition, structural components of biofilms, and molecular interactions regarding metabolism- and communication pathways within the biofilm, such as uptake of administered drugs or inter-bacteria communication, remains elusive. Imaging these molecules and their distribution in the biofilm increases insight into biofilm development, growth, and response to environmental factors or drugs. This systematic review provides an overview of molecular imaging techniques used for bacterial biofilm imaging. The techniques included mass spectrometry-based techniques, fluorescence-labelling techniques, spectroscopic techniques, nuclear magnetic resonance spectroscopy (NMR), micro-computed tomography (µCT), and several multimodal approaches. Many molecules were imaged, such as proteins, lipids, metabolites, and quorum-sensing (QS) molecules, which are crucial in intercellular communication pathways. Advantages and disadvantages of each technique, including multimodal approaches, to study molecular processes in bacterial biofilms are discussed, and recommendations on which technique best suits specific research aims are provided.

7 January 2021 in Analytical Chemistry
Verified
Journal Article
Open access
SMStephanie T. P. Mezger
Stephanie T. P. Mezger
AMAlma M. A. Mingels
Alma M. A. Mingels
OBOtto Bekers
Otto Bekers
RHRon M. A. Heeren
Ron M. A. Heeren
BCBerta Cillero-Pastor
Berta Cillero-Pastor
Mass spectrometry imaging (MSI) can analyze the spatial distribution of hundreds of different molecules directly from tissue sections usually placed on conductive glass slides to provide conductivity on the sample surface. Additional experiments are often required for molecular identification using consecutive sections on membrane slides compatible with laser capture microdissection (LMD). In this work, we demonstrate for the first time the use of a single conductive slide for both matrix-assisted laser desorption ionization (MALDI)-MSI and direct proteomics. In this workflow, regions of interest can be directly ablated with LMD while preserving protein integrity. These results offer an alternative for MSI-based multimodal spatial-omics.

28 August 2024 in The Analyst
Verified
Journal Article
Open access
PDF file
MVMudita Vats
Mudita Vats
BCBerta Cillero-Pastor
Berta Cillero-Pastor
ECEva Cuypers
Eva Cuypers
RHRon M. A. Heeren
Ron M. A. Heeren
Mass spectrometry imaging (MSI) provides spatially-resolved molecular information across various samples, including plants, microbes, and food, thereby enhancing our understanding of agricultural systems.

13 November 2018 in Analytical Chemistry
Verified
Journal Article
Open access
FBFlorian P.Y. Barré
Florian P.Y. Barré
BCBritt S.R. Claes
Britt S.R. Claes
FDFrédéric Dewez
Frédéric Dewez
CPCarine J. Peutz-Kootstra
Carine J. Peutz-Kootstra
HMHelga F. Munch-Petersen
Helga F. Munch-Petersen
BCBerta Cillero-Pastor
Berta Cillero-Pastor
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma. To treat this aggressive disease, R-CHOP, a combination of immunotherapy (R; rituximab) and chemotherapy (CHOP; cyclophosphamide, doxorubicin, vincristine and prednisone), remains the most commonly used regimen for newly diagnosed DLBCLs. However, up to one-third of patients ultimately becomes refractory to initial therapy or relapses after treatment, and the high mortality rate highlights the urgent need for novel therapeutic approaches based upon selective molecular targets. In order to understand the molecular mechanisms underlying relapsed DLBCL and to find better therapeutic targets, we studied differences in the chemical composition after R-CHOP treatment and tumor relapse, using a combination of in vivo DLBCL xenograft models and mass spectrometry imaging. Together, these techniques provide information regarding analyte composition and molecular distributions of therapy-resistant and sensitive areas. We found specific lipid and metabolic profiles for R-CHOP–resistant tumors such as a higher presence of phosphatidylinositol and sphingomyelin fragments. In addition, we investigated intratumor heterogeneity and identified specific lipid markers of viable and necrotic areas. Furthermore, we could monitor metabolic changes, and found reduced adenosine triphosphate and increased adenosine monophosphate in the R-CHOP–resistant tumors. This work highlights the power of combining in vivo imaging and MSI to track molecular signatures in DLBCL, which has potential application for other diseases.